Cardiff, Oncology

Cardiff Oncology Wins FDA Fast Track for Onvansertib as Colorectal Data Mature

Published on 11/17/2026 at 01:20 | Editorial boerse-global.de
FDA grants fast-track status to Onvansertib plus FOLFIRI/Bevacizumab for first-line KRAS/NRAS-mutant metastatic colorectal cancer; shares rise about 20%.
Cardiff Oncology Illustration mit AI erstellt.

Cardiff Oncology picked up a regulatory boost on Friday, with the US Food and Drug Administration granting fast-track designation to Onvansertib in combination with FOLFIRI/Bevacizumab. The designation covers first-line treatment of adult patients with metastatic colorectal cancer carrying a KRAS or NRAS mutation. Shares climbed roughly 20% on the day.

The fast-track nod rests on data from the ongoing Phase 2 CRDF-004 trial. At the proposed 30 mg dose, the Onvansertib combination produced a confirmed objective response rate of 72.2%, according to the company, against 42.1% for FOLFIRI/Bevacizumab alone. Median progression-free survival in the 30 mg combination arm had not yet been reached.

Durability appears to be building alongside the response figures. Patients in the Onvansertib plus FOLFIRI/Bevacizumab arm have now been on treatment for more than 21 months, with the longest duration exceeding 29 months. By contrast, media reports indicate that only six patients remained on the FOLFIRI/Bevacizumab-only regimen at the end of September.

Should investors sell immediately? Or is it worth buying Cardiff Oncology?

Cash Runway and Going-Concern Warning

Cardiff's third-quarter 2026 report, released Thursday, showed a net loss of $8.9 million, or $0.12 per share, on revenue of $171,000. As of September 30, the company held roughly $33.8 million in cash, cash equivalents and short-term investments — a balance management expects to fund operations through the end of the third quarter of 2027. The 10-Q filing, however, disclosed substantial doubt about Cardiff's ability to continue as a going concern.

That funding question hangs directly over the pivotal Phase 3 program, which the company targets for the first quarter of 2027. Cardiff has attached an explicit caveat to that timeline: the launch depends on securing additional financing.

The fast-track decision is not the only regulatory milestone of late. On November 9, the FDA awarded Onvansertib orphan-drug status for small-cell lung cancer — a designation that does not constitute marketing approval.

Management was scheduled to present at the UBS Global Biopharma Conference on Friday, with investor meetings planned for Friday and Saturday.

Ad

Cardiff Oncology Stock: New Analysis - 17 November

Fresh Cardiff Oncology information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Cardiff Oncology analysis...

Disclaimer...
en | US14147L1089 | CARDIFF | boerse | 70523275 |